Nanoparticle-Cell Conjugates for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticle-based drug delivery systems for cancer management suffer from low targeting specificity and efficiency, leading to wide bio-distribution and significant side effects due to chance-dependent recognition, resulting in inadequate delivery of therapeutic agents to cancer cells.
Innovation Solution
Development of nanoparticle-cell conjugates using biodegradable photoluminescent polymers and immune cells, such as THP-1 macrophages, that actively target and deliver therapeutic agents like PLX4032 to melanoma cells through specific interactions, enhancing targeting efficiency and minimizing cytotoxicity to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nanoparticles are injected into circulation to deliver therapeutic agents, then drug delivery capability is improved, but targeting specificity deteriorates resulting in wide bio-distribution and side effects
Solution Approach 1:
The patent uses immune cells (macrophages) as intermediary carriers that actively navigate to tumor sites. The nanoparticles are delivered by these living cells rather than passive circulation, with the cells serving as mediators that provide both transport and active targeting functions, resolving the contradiction between delivery capability and targeting precision
Solution Approach 2:
The patent transitions from static nanoparticle delivery to dynamic cell-mediated delivery. The immune cells are alive and actively migrate to tumor sites, providing dynamic targeting capability that adapts to the biological environment, thereby improving both delivery efficiency and targeting specificity simultaneously
2Manufacturing precision
If targeting ligands are used to guide nanoparticles to cancer cells, then active targeting is improved, but reliability of specific delivery deteriorates due to chance-dependent recognition
Solution Approach 1:
The immune cells used as carriers possess innate homing capabilities to tumor sites through their biological programming. They self-navigate to cancer locations without requiring external guidance ligands, making the targeting process more reliable and less dependent on chance molecular recognition events
Solution Approach 2:
The immune cell acts as an intelligent intermediary that combines active targeting with reliable delivery. The cell's biological navigation system provides consistent and reliable targeting to tumor sites, overcoming the unreliability of passive ligand-receptor interactions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach achieves targeted and controlled release of therapeutic agents directly to cancer cells, reducing side effects and improving therapeutic outcomes by utilizing immune cells as navigators and carriers for nanoparticles, ensuring high uptake and effective delivery of chemotherapeutics.
Implementation Method 1
The nanoparticle comprises at least one of a therapeutic-agent and a biodegradable photoluminescent polymer (BPLP)
Implementation Method 2
an enzyme-sensitive degradable peptide comprising a first clickable moiety or a pH sensitive degradable polymer comprising a first clickable moiety
Implementation Method 3
a pH sensitive degradable polymer comprising a first clickable moiety
Implementation Method 4
the first clickable moiety of the enzyme degradable peptide or of the pH sensitive polymer reacts with a second clickable moiety on a surface of a cell, via a click chemistry reaction, to form a nanoparticle-cell conjugate
Data Source
AI summary
In one aspect, methods of targeted nanoparticles and cell delivery are described herein. In some embodiments methods described herein comprise coupling nanoparticles and cells to a carrier cell to form a nanoparticle-cell conjugate or cell-cell conjugate, disposing the nanoparticle-cell or cell-cell conjugate in a biological environment, and delivering the nanoparticles and cells to target cells or tissues located within the biological environment. The nanoparticles comprise a biodegradable photoluminescent polymer, and the nanoparticle-cell conjugate is formed using one or more click chemistry reaction products.